Australian tech company opens new US office, eyes FDA approval for AI CAD solution
Artrya Limited, an Australian healthcare technology company focused on diagnosing coronary artery disease (CAD), has expanded its operations to the United States.
The company opened its new U.S. subsidiary, Artrya USA, in Los Angeles. Ted Schwab and Jory Tremblay, two industry veterans with more than 30 years of experience each, will serve as co-CEOs.
“This is an important strategic move in bringing Artrya Salix to the U.S. and the strong health industry backgrounds of Ted and Jory will be of tremendous value,” John Barrington, Artrya’s managing director and co-founder, said in a statement. “The United States market is significant with over $200 billion spent every year on cardiovascular disease. Representing 34% of the global market, it is timely for Artrya to establish U.S. operations and we are extremely fortunate to have two such qualified individuals leading our entrance into the U.S. market.”
Artrya Salix, an AI-powered solution for CAD detection, is the company’s flagship offering. It was designed to identify signs of atherosclerotic plaque on 3D images of a patient’s heart, providing full reports in approximately 15 minutes. Artrya hopes to gain FDA approval in the months ahead.
Back in January, Jacque Sokolov, MD, chairman and CEO of SSB Solutions, was announced as the new chair of the Artrya Clinical Advisory Board. Sokolov is a trained cardiologist with decades of experience as a renowned healthcare executive. He has played an advisory role for four different U.S. presidents.
“I look forward to building networks with key opinion leaders and subject matter experts as we introduce technology designed to more effectively help cardiologists diagnose and treat heart disease,” Sokolov said at the time.
Related Economics Content:
VIDEO: Creating a telecardiology program
Telecardiology during the COVID-19 pandemic showed cardiologists another way to treat patients
Severe financial strain more than doubles risk of death among heart attack patients
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.